Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Men
Shots:
- The P-III ARCHES trial involves assessing of Xtandi + ADT (enzalutamide- 160mg) vs ADT monothx in 1-150 men with mHSPC at the US- Canada- EU- South America
- P-III ARCHES study results: reducing the risk of radiographic progression or death by 61%; reduced the risk of PSA progression- antineoplastic therapy & deterioration in urinary symptoms; Undetectable PSA (68.1% vs 17.6%); ORR (83.1% vs 63.7%); GRADE 3 or 4 AEs (23.6% vs 24.7%)
- Xtandi (enzalutamide) is an androgen receptor inhibitor targeted for astration-resistant prostate cancer. In Oct 2009- Pfizer & Astellas globally collaborated to jointly develop & commercialize enzalutamide in the US
Ref: Astellas | Image:Astellas
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com